1. Home
  2. MGTX vs HELP Comparison

MGTX vs HELP Comparison

Compare MGTX & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MeiraGTx Holdings plc

MGTX

MeiraGTx Holdings plc

BUY

Current Price

$10.89

Market Cap

1.0B

Sector

Health Care

ML Signal

BUY

Logo Cybin Inc. Common Stock

HELP

Cybin Inc. Common Stock

N/A

Current Price

$11.43

Market Cap

854.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MGTX
HELP
Founded
2015
N/A
Country
United States
Canada
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
854.9M
IPO Year
2018
2020

Fundamental Metrics

Financial Performance
Metric
MGTX
HELP
Price
$10.89
$11.43
Analyst Decision
Buy
Strong Buy
Analyst Count
8
11
Target Price
$27.75
★ $39.84
AVG Volume (30 Days)
932.9K
★ 1.7M
Earning Date
11-12-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 33.02
N/A
EPS
★ 1.30
N/A
Revenue
★ $81,391,000.00
N/A
Revenue This Year
$314.19
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$8.40
★ N/A
Revenue Growth
★ 144.57
N/A
52 Week Low
$6.62
$3.76
52 Week High
$15.35
$15.15

Technical Indicators

Market Signals
Indicator
MGTX
HELP
Relative Strength Index (RSI) 31.37 42.75
Support Level $8.84 $4.41
Resistance Level $11.85 $14.75
Average True Range (ATR) 0.58 0.89
MACD -0.18 -0.29
Stochastic Oscillator 13.29 6.51

Price Performance

Historical Comparison
MGTX
HELP

About MGTX MeiraGTx Holdings plc

MeiraGTx Holdings PLC is a vertically integrated, clinical-stage genetic medicines company focused on developing targeted therapies for diseases with high unmet need, including radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy. The company's pipeline is supported by end-to-end in-house manufacturing capabilities, including GMP viral vector production, plasmid manufacturing, and quality control, enabling development from IND to commercial supply. It also utilizes proprietary platforms in viral vector optimization and riboswitch-based gene regulation to enhance efficacy and reduce dosage. The company operates in the United States, the United Kingdom, and the European Union.

About HELP Cybin Inc. Common Stock

Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.

Share on Social Networks: